JBIO - Aerovate Therapeutics, Inc.

QQQ $ 608.59 $ -9.26 (-1.5 %)

DIA $ 475.50 $ -6.59 (-1.37 %)

SPY $ 672.57 $ -8.41 (-1.24 %)

TLT $ 89.38 $ -0.42 (-0.46 %)

GLD $ 384.40 $ -4.31 (-1.11 %)

Previous Close

$ 9.68

Open

$ 9.85

Bid

$ 8.00 x 2

Ask

$ 10.50 x 2

Day's Range

-- - --

52 Week Range

$ 6.57 - $ 13.50

Volume

77,023

Average Volume

Market Cap

315.83M

Beta (5Y Monthly)

$ 0.84

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.25)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	04-25-2025	03-31-2025	10-Q
3	03-27-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-13-2024	03-31-2024	10-Q
7	03-25-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-29-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-30-2022	12-31-2021	10-K
16	11-15-2021	09-30-2021	10-Q
17	08-16-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Jade Biosciences Q3 EPS $(0.48) Beats $(0....
11/13/2025 21:33:52

Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0....

Reported Saturday, Jade Biosciences Presen...
11/10/2025 09:11:37

Jade Biosciences To Present New Preclinica...
10/17/2025 20:09:01

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" ...

BTIG Initiates Coverage On Jade Bioscience...
10/09/2025 10:09:45

BTIG analyst Julian Harrison initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating and announces Price Targ...

Jade Biosciences announces PIPE financing ...
10/07/2025 11:07:57

Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of (i) 13,368,164 shares of its common...

Jade Biosciences Unveils JADE201, Investig...
10/07/2025 11:06:34

12 Health Care Stocks Moving In Wednesday'...
10/01/2025 21:05:58

Jade Biosciences Starts Phase 1 Trial Of J...
09/02/2025 11:03:34

Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused...

Wedbush Maintains Outperform on Jade Biosc...
08/14/2025 14:02:58

Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $17 ...

Jade Biosciences Q2 EPS $(0.86) Misses $(0...
08/13/2025 20:15:53

abbott-laboratories-issues-weak-earnings-forecast-joins-mp-materials-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

Abbott Laboratories Issues Weak Earnings F...
07/17/2025 12:39:47

12 Health Care Stocks Moving In Thursday's...
07/17/2025 12:08:10

why-sarepta-therapeutics-shares-are-trading-higher-by-34-here-are-20-stocks-moving-premarket

Why Sarepta Therapeutics Shares Are Tradin...
07/17/2025 10:15:10

Jade Biosciences Appoints Brad Dahms As Ch...
07/01/2025 11:04:50

Guggenheim Upgrades Jade Biosciences to Bu...
06/16/2025 13:35:46

Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy and announces $14 price target.

12 Health Care Stocks Moving In Monday's P...
06/09/2025 12:08:42

Jade Biosciences Presents Detailed Preclin...
06/09/2025 11:03:16

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approxima...

Jade Biosciences Announced New Preclinical...
06/02/2025 11:12:22

Wedbush Reiterates Outperform on Jade Bios...
05/15/2025 14:57:32

Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $17 price target.

Jade Biosciences Q1 EPS $(12.10) Misses $(...
05/14/2025 20:42:56

Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $...